Maia Biotechnology Stock Today
| MAIA Stock | USD 2.18 0.04 1.80% |
Performance0 of 100
| Odds Of DistressOver 85
|
MAIA Biotechnology is trading at 2.18 as of the 29th of November 2024, a 1.8% down since the beginning of the trading day. The stock's open price was 2.22. MAIA Biotechnology has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for MAIA Biotechnology are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 2nd of June 2024 and ending today, the 29th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 28th of July 2022 | Category Healthcare | Classification Health Care |
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. The company was founded in 2018 and is headquartered in Chicago, Illinois. The company has 25.33 M outstanding shares of which 662.41 K shares are now shorted by private and institutional investors with about 10.99 trading days to cover. More on MAIA Biotechnology
Moving against MAIA Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
MAIA Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Old Names | [CMB, CMB (MAIA.SG), CMB - Frankfurt Stock Exchang] | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
MAIA Biotechnology can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand MAIA Biotechnology's financial leverage. It provides some insight into what part of MAIA Biotechnology's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
MAIA Biotechnology (MAIA) is traded on NYSE MKT Exchange in USA. It is located in 444 West Lake Street, Chicago, IL, United States, 60606 and employs 13 people. MAIA Biotechnology is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 55.22 M. MAIA Biotechnology conducts business under Biotechnology sector and is part of Health Care industry. The entity has 25.33 M outstanding shares of which 662.41 K shares are now shorted by private and institutional investors with about 10.99 trading days to cover.
MAIA Biotechnology currently holds about 8.15 M in cash with (13.07 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.75.
Check MAIA Biotechnology Probability Of Bankruptcy
Ownership AllocationMAIA Biotechnology maintains a total of 25.33 Million outstanding shares. MAIA Biotechnology secures 17.49 % of its outstanding shares held by insiders and 7.5 % owned by institutional investors. Please note that no matter how many assets the company has, if the real value of the entity is less than the current market value, you may not be able to make money on it.
Check MAIA Ownership Details
MAIA Biotechnology Historical Income Statement
MAIA Stock Against Markets
MAIA Biotechnology Corporate Management
| MD MBA | President, CoFounder | Profile | |
| Joseph McGuire | Chief Officer | Profile | |
| Sergei Gryaznov | Chief Officer | Profile | |
| Jeffrey Himmelreich | Head Finance | Profile | |
| Mihail MD | Chief Devel | Profile | |
| Linda Moreira | Company Secretary | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MAIA Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For information on how to trade MAIA Stock refer to our How to Trade MAIA Stock guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MAIA Biotechnology. If investors know MAIA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about MAIA Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.34) | Return On Assets (1.07) | Return On Equity (5.60) |
The market value of MAIA Biotechnology is measured differently than its book value, which is the value of MAIA that is recorded on the company's balance sheet. Investors also form their own opinion of MAIA Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is MAIA Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because MAIA Biotechnology's market value can be influenced by many factors that don't directly affect MAIA Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between MAIA Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if MAIA Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, MAIA Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.